Barclays PLC Raises Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Barclays PLC grew its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 16.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 99,148 shares of the company's stock after acquiring an additional 13,753 shares during the period. Barclays PLC owned about 0.16% of Vera Therapeutics worth $4,192,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Huntington National Bank acquired a new position in Vera Therapeutics during the 4th quarter worth $26,000. AlphaQuest LLC purchased a new position in shares of Vera Therapeutics in the 4th quarter valued at about $34,000. KBC Group NV grew its position in shares of Vera Therapeutics by 127.2% during the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after buying an additional 1,387 shares in the last quarter. Summit Investment Advisors Inc. increased its stake in shares of Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after buying an additional 639 shares during the period. Finally, Moors & Cabot Inc. acquired a new stake in Vera Therapeutics in the fourth quarter valued at approximately $220,000. Hedge funds and other institutional investors own 99.21% of the company's stock.

Vera Therapeutics Trading Down 1.1 %

VERA opened at $23.22 on Monday. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $51.61. The business's 50 day moving average is $25.27 and its two-hundred day moving average is $35.86. The firm has a market cap of $1.48 billion, a price-to-earnings ratio of -8.90 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.11. On average, research analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Wolfe Research began coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective on the stock. Guggenheim increased their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. The Goldman Sachs Group started coverage on Vera Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target for the company. Finally, JPMorgan Chase & Co. dropped their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $64.67.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.